Historically, there has been limited evidence to suggest the appropriate treatment sequencing of this melanoma patient population. However, new findings demonstrate starting with Opdivo plus Yervoy ...

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of ...

Positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy versus chemotherapy as neoadjuvant therapy in a Phase 3 trial in resectable non ...

Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the ...

Bristol Myers Squibb (BMY Quick Quote BMY - Free Report) announced that the European Commission has approved the combination of its blockbuster immuno-oncology drug Opdivo (nivolumab) and Yervoy ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

Please provide your email address to receive an email when new articles are posted on . Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor. If approved, it will be the only PD-1 ...

Opdivo's wider non-small cell lung cancer approval comes two years after its approval as a pre-surgery treatment in the disease setting. (Bristol Myers Squibb) Hot on the tail of AstraZeneca’s Imfinzi ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

Doctors may recommend nivolumab (Opdivo) adjuvant for some people with bladder cancer. This includes those with a high risk of recurrence following bladder surgery and people who have received ...